Brennan has served on Spectrum's board of directors and as chairperson of the audit committee since December 2020, and will relinquish her board duties to assume this new role.
Most recently, Brennan served as chief financial officer of Fore Biotherapeutics, a private precision oncology company pioneering the development of cancer therapies driven by functional genomics.
Prior to Fore, she was the chief financial officer of Tela Bio, Inc., where she guided the company through a successful IPO and follow-on financing.
Previously, Brennan spent 11 years as the senior vice president of Treasury and Investor Relations at Integra LifeSciences Holdings Corp., where she served in numerous capacities and led Integra through a myriad of financings.
She was key to the capital markets strategy over a significant period of time and successfully integrated 18 acquisitions leading to significant revenue growth for the company.
She earned her B.A. in Economics from the University of Illinois at Urbana-Champaign and received her MBA from the University of Chicago Booth School of Business.
With Brennan's announcement, Brittany Bradrick, who was recently appointed to the board, will now assume the role of chairperson of the audit committee.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.
Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace.
Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need.
This pipeline has the potential to transform the company in the near future.
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development